CNS Pharmaceuticals, Inc.
CNSP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$4.97
KIRA · Stoqly’s AI analyst, in plain words
- CNS Pharmaceuticals, Inc. lost $15.9M in fiscal 2025.
- Free cash flow was −$13.8M in fiscal 2025, — of revenue.
Market cap
$34.0M
P/E
—
Revenue
—
Net income
−$15.9M
Free cash flow
−$13.8M
Operating margin
—
CNS Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$15.9M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What CNS Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- CNS Pharmaceuticals, Inc.
- CIK
- 0001729427
CNS Pharmaceuticals, Inc. · CNSP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$14.5M | −$15.3M | −$18.9M | −$14.9M | −$15.9M |
| Diluted EPS | −$16.50 | −$11.22 | −$12,509.11 | −$466.89 | −$35.75 |
| Cash | |||||
| Cash from operations | −$13.5M | −$10.6M | −$14.1M | −$17.1M | −$13.8M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$13.5M | −$10.6M | −$14.1M | −$17.1M | −$13.8M |
| Share count change | −94.7% | 55.0% | −99.9% | 2,020.0% | 1,294.3% |
| Debt and strength | |||||
| Cash and short-term investments | $5.0M | $10.1M | $0.5M | $6.5M | $7.2M |
| Shareholders' equity | $6.2M | $8.1M | −$4.4M | $6.2M | $4.5M |
| Current ratio | 2.9x | 2.6x | 0.3x | 3.4x | 2.0x |
| Interest coverage | −1,557.6x | −2,181.0x | −1,367.0x | −925.6x | −1,051.8x |
| Returns and quality | |||||
| Return on equity | −144.2% | −213.7% | −1,018.8% | −1,703.0% | −296.3% |
| Return on tangible equity | −235.2% | −187.8% | — | −240.5% | −350.4% |
| Altman Z'' | −18.2 | −14.9 | −226.1 | −35.9 | −46.2 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CNS Pharmaceuticals, Inc. · CNSP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.97 a share, the company is worth $34.0M.
Source: SEC EDGAR XBRL filings (CIK 0001729427). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.